The endocannabinoid system: A new paradigm in the metabolic syndrome treatment;O sistema endocanabinóide: Novo paradigma no tratamento da síndrome metabólica

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 50, Issue 2, 2006, Pages 390-399

  De Godoy Matos, Amélio F ^a   Guedes, Erika Paniago ^a   De Souza, Luciana Lopes ^a   Valério, Cynthia Melissa ^a  

^a Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione   (Brazil)

Author keywords

Endocannabinoid; Metabolic syndrome; Obesity; Rimonabant

Indexed keywords

CANNABINOID RECEPTOR; ENDOCANNABINOID;

ANIMAL; DISEASE MODEL; DRUG POTENTIATION; ENERGY METABOLISM; FEEDING BEHAVIOR; HUMAN; METABOLIC SYNDROME X; METABOLISM; OBESITY; PHYSIOLOGY; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; ENERGY METABOLISM; FEEDING BEHAVIOR; HUMANS; METABOLIC SYNDROME X; OBESITY; RECEPTORS, CANNABINOID;

EID: 33744469579     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302006000200025     Document Type: Review

References (55)

1. Webber J. Energy balance in obesity. Proc Nutr Soc 2003;62:539-43.
2. Flegal KM. Epidemiologic aspects of overweight and obesity in the United States. Physiol Behav 2005;86:599-602.
3. Berenson GS. Obesity - a critical issue in preventive cardiology: the Bogalusa Heart Study. Prev Cardiol 2005;8:234-41.
4. Smith R, Fathi Z. Recent advances in the development and research of CB1 antagonists. Drugs 2005;8:55-63.
5. Di Marzo V, Bifulco M, Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Disc 2004;3:771-84.
6. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005;8:585-9.
7. Gaoni Y, Mechoulan R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646-7.
8. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-4.
9. Cota D, Marsiano G, Lutz B, Vicennati V, Stalla GK, Pasquali R, et al. Endogenous cannabinoid system as a modulator of food intake. Int J Obes 2003;27:289-301.
10. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacol 2004;47:345-58.
11. Cox SL. Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors. Drugs Today (Barc) 2005;41:499-508.
12. Cabral GA, Dove Pettit DA. Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. J Neuroimmunol 2005;83:116-23.
13. Howlett AC. The cannabinoid receptors. Prostaglandins Other Lipid Mediat 2002;68-9:619-31.
14. De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 2004;141:765-74.
15. Christie MJ, Vaughan CW. Neurobiology: Cannabinoids act backwards. Nature 2001;410:527-30.
16. Sipe JC, Waalen J, Gerber A, Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes 2005;29:755-9.
17. Engeli S, Böhnke J, Feldpausch M, Gorzelniak K, Janke J, Bátkai S, et al. Activation of the peripheral Endocannabinoid system in human obesity. Diabetes 2005;2838-43.
18. Sipe JC, Chiang K, Gerber AL, Beutlar E, Cravatt BF. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. PNAS 2002;99:8394-9.
19. Godoy-Matos AF. O sistema canabinóide. In: Godoy-Matos AF, editor. Síndrome metabólica. São Paulo: Atheneu, 2005.
20. Cota D, Marsicano G, Tschöp M, Grübler Y, Flachskamm C, Schubert M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003;112:423-31.
21. Cani PC, Montoya ML, Neyrinck AM, Delzenne NM, Lambert DM. Short communication - Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. Br J Nutr 2004;92:757-61.
22. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002;136:550-7.
23. Jamshidi N, Taylor DA. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 2001;134:1151-4.
24. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001;412:822-5.
25. Monteleone P, Matias I, Martiadis V, De Petrocellis L, Maj M, Di Marzo V. Blood levels of the endocannabinoid anandanida are increased in anorexia nervosa and binge-eating disorder, but not in Bulimia Nervosa. Neuropsycopharmacol 2005;30:1216-21.
26. Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002;22:9612-27.
27. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated from stomach. Nature 1999;402:656-60.
28. Giuffrida A, Beltramo M, Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther 2001;298:7-14.
29. Trillou C R, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Comp Physiol 2003;284:R345-53.
30. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004;28:640-8.
31. Jbilo O, Ravinet-Trillou C, Arnone N, Buisson I, Bribes E, et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lypolisis and energy balance. FASEB J 2005;19:1567-9.
32. Heilbronn L, Smith SR, Ravussin E. Failure of fats cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type 2 diabetes mellitus. Inter J Obes 2004;28:S12-S21.
33. Unger RH. Mini review: Weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003;144:5159-65.
34. Ali AT, Crowther NJ. Body fat distribution and insulin resistance. SAMJ 2005;95:878-90.
35. Bensaid M, Gary-Bobo M, Esclangon A. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured cells. Mol Pharmacol 2003;63:908-14.
36. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. Metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005;143:722-8.
37. Medina J, García-Buey L, Fernandez-Salazar LI, Moreno-Otero R. Approach to the pathogenesis and treatment of non alcoholic steatohepatitis. Diabetes Care 2004;27:2057-66.
38. Diehl AM, Li ZP, Lin HZ, Iang SQ. Cytoquines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005;54:303-6.
39. Baneji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab 1999;84:137-44.
40. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000;21:697-738.
41. Thamer C, Machann J, Haap M, Stefan N, Heller E, Schnödt B, et al. Intrahepatic lipids are predicted by visceral adipose tissue mass in healthy subjects. Diabetes Care 2004;27:2726-9.
42. Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD. Splanchnic lipolysis in human obesity. J Clin Invest 2004;113:1582-8.
43. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004;114:147-52.
44. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Bátkai S, et al. Endocannabinoid action at hepatic CB1 receptors regulates fatty acid synthesis: role in dietinduced obesity. J Clin Invest 2005;115:1298-305.
45. Dale L, Anthenelli R, Despres J-P, Golay A, Sjostrom L. Effects of rimonabant in the reduction of major cardiovascular risk factors. Results from the STRATUS-US Trial (Smoking Cessation in Smokers Motivated to Quit) and the RIO-Lipids Trial (Weight Reducing and Metabolic Effects in Overweight/Obese Patients with Dyslipidemia). Late-Breaking Clinical Trials II. American College of Cardiology Scientific Session 2004, March 7-10, 2004, New Orleans, Louisiana.
46. Van Gaal L. RIO-Europe: a randomized double-blind study of weight reducing effect and safety of rimonabant in obese patients with or without comorbidities. Hot Line I - Prevention and medical treatment I. ESC Congress 2004, August 28 - September 1, 2004, Munich, Germany.
47. Van Gaal LF, Rissanen A, Scheen AJ, Ziegler O, Rössner S; the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97.
48. Després JP, Golay A, Sjöström L, the Rimonabant in Obesity-Lipids Study group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. NEJM 2005;353:2121-34.
49. Tobacco or health: A global status report. Geneva: World Health Organization, 1997.
50. Centers for Disease Control and Prevention. Annual smoking-attributable mortality, years of potential life lost, and economic costs - United States, 1995-1999. Morb Mortal Wkly Rep 2002;51:300-3.
51. Godtfredsen NS, Holst C, Prescott E, Vestbo J, Osler M. Smoking reduction, smoking cessation, and mortality: a 16-year follow-up of 19,732 men and women from The Copenhagen Centre for Prospective Population Studies. Am J Epidemiol 2002;156:994-1001.
52. Balfour DJ. Neuroplasticity within the mesoaccumbens dopamine system and its role in tobacco dependence. Curr Drug Targets CNS Neurol Disord 2002;1:413-21.
53. De Vries TJ, De Vries W, Janssen MCW, Schoffelmeer ANM. Suppression of conditioned nicotine and sucrose seeking by the cannabinoid-1 receptor antagonist SR141716A. Behav Brain Res 2005;161:164-8.
54. Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML. Pharmacotherapy for Nicotine Dependence. CA Cancer J Clin 2005;55:281-99.
55. Anthenelli R. Smoking cessation in smokers motivated to quit. Presented at: American College of Cardiology Scientific Sessions; March 7-10, 2004; New Orleans, LA.